Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes


KUEMMERLE-DESCHNER J. B. , HACHULLA E., CARTWRIGHT R., Hawkins P. N. , TRAN T. A. , Bader-Meunier B., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.70, ss.2095-2102, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 70 Konu: 12
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1136/ard.2011.152728
  • Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
  • Sayfa Sayıları: ss.2095-2102

Özet

Objective Longer-term effects of prolonged selective interleukin-1 beta blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.